This database contains 21 studies, archived under the term: "statistics nonparametric"
Click here to filter this large number of results.
Effects of lexical-semantic treatment on memory in early Alzheimer disease: an observer-blinded randomized controlled trial
Jelcic, Nela,
Cagnin, Annachiara,
Meneghello, Francesca,
Turolla, Andrea,
Ermani, Mario,
Dam, Mauro
Background: Episodic memory and semantic abilities deteriorate early in Alzheimer disease (AD). Since the cognitive system includes interconnected and reciprocally influenced neuronal networks, the authors hypothesized that stimulation of lexical-semantic abilities may benefit semantically structured episodic memory.; Objective: To investigate the effects of lexical-semantic stimulation (LSS) on verbal communication and episodic memory in early AD.; […]
Mnemonic strategy training improves memory for object location associations in both healthy elderly and patients with amnestic mild cognitive impairment: a randomized, single-blind study
Hampstead, Benjamin M.,
Sathian, Krish,
Phillips, Pamela A.,
Amaraneni, Akshay,
Delaune, William R.,
Stringer, Anthony Y.
Objective: To evaluate the efficacy of mnemonic strategy training versus a matched-exposure control condition and to examine the relationship between training-related gains, neuropsychological abilities, and medial temporal lobe volumetrics in patients with amnestic mild cognitive impairment (aMCI) and age-matched healthy controls.; Method: Twenty-three of 45 screened healthy controls and 29 of 42 screened patients with […]
A proteomics study reveals a predominant change in MaoB expression in platelets of healthy volunteers after high protein meat diet: relationship to the methylation cycle
Zellner, Maria,
Babeluk, Rita,
Jakobsen, Lene H.,
Gerner, Christopher,
Umlauf, Ellen,
Volf, Ivo,
Roth, Erich,
Kondrup, Jens
Studies investigating the impact of high meat intake on cognition have yielded contradictory results as some show improved cognitive performance, whereas others report an increase of risk factors for dementia. However, few studies were designed to directly assess the effect of a high protein (HP) diet on both cognitive performance and corresponding biochemical parameters. A […]
Magnetic resonance imaging and neuropsychological results from a trial of memantine in Alzheimer’s disease
Weiner, Michael W.,
Sadowsky, Carl,
Saxton, Judith,
Hofbauer, Robert K.,
Graham, Stephen M.,
Yu, Sung Yun,
Li, Shaoyi,
Hsu, Hai-An,
Suhy, Joyce,
Fridman, Moshe,
Perhach, James L.
Background: This study was designed to assess changes in brain volume and cognitive abilities in memantine-treated patients with Alzheimer’s disease (AD) by using an exploratory, single-arm, delayed-start design.; Methods: Cholinesterase inhibitor-treated patients with AD (N = 47; Mini-Mental State Examination score range: 15-23) were enrolled in an observational lead-in period (weeks: 1-24), followed by an […]
Effect of an antioxidant drink on homocysteine levels in Alzheimer’s patients
Morillas-Ruiz, J. M.,
Rubio-Perez, J. M.,
Albaladejo, M. D.,
Zafrilla, P.,
Parra, S.,
Vidal-Guevara, M. L.
Background: A large body of evidence supports a role of oxidative stress in Alzheimer disease (AD) and in cerebrovascular disease. Blood levels of homocysteine may be increased in AD and hyperhomocysteinemia may contribute to disease pathophysiology by vascular and direct neurotoxic mechanisms. Even in the absence of vitamin deficiency, plasma total homocysteine (tHcy) concentration may […]
Treadmill training as an augmentation treatment for Alzheimer’s disease: a pilot randomized controlled study
Arcoverde, Cynthia,
Deslandes, Andrea,
Moraes, Helena,
Almeida, Cloyra,
Araujo, Narahyana Bom de,
Vasques, Paulo Eduardo,
Silveira, Heitor,
Laks, Jerson
Objective: To assess the effect of aerobic exercise on the cognition and functional capacity in Alzheimer’s disease (AD) patients.; Method: Elderly (n=20) with mild dementia (NINCDS-ADRDA/CDR1) were randomly assigned to an exercise group (EG) on a treadmill (30 minutes, twice a week and moderate intensity of 60% VO₂max) and control group (GC) 10 patients. The […]
Treatment of behavioral and psychological symptoms of Alzheimer-type dementia with Yokukansan in clinical practice
Hayashi, Yoshihito,
Ishida, Yasushi,
Inoue, Teruhiko,
Udagawa, Mitsutaka,
Takeuchi, Kouzou,
Yoshimuta, Hirofumi,
Kiue, Kouichirou,
Ninomiya, Yoshimasa,
Kawano, Jiro,
Sameshima, Tetsuro,
Kawahara, Takashi,
Goto, Isamu,
Shudo, Kenji,
Kurayama, Shigeki,
Nakamura, Jungo,
Okahara, Kazunori,
Mitsuyama, Yoshio
The efficacy and safety of the kampo medicine Yokukansan (YKS, TJ-54) in the treatment of behavioral and psychological symptoms of dementia (BPSD) were investigated in patients with Alzheimer’s disease (AD) in an open-label study. This study included 26 patients who had been diagnosed as having AD and were not treated with donepezil hydrochloride. These patients […]
Prazosin for the treatment of behavioral symptoms in patients with Alzheimer disease with agitation and aggression
Wang, Lucy Y.,
Shofer, Jane B.,
Rohde, Kirsten,
Hart, Kim L.,
Hoff, David J.,
McFall, Yun H.,
Raskind, Murray A.,
Peskind, Elaine R.
Objectives: Agitation/aggression in Alzheimer disease (AD) is a major cause of patient distress, caregiver burden, and institutionalization. Enhanced behavioral responsiveness to central nervous system norepinephrine (NE) release may contribute to the pathophysiology of agitation/aggression in AD. Prazosin, a nonsedating generic medication used for hypertension and benign prostatic hypertrophy, antagonizes NE effects at brain postsynaptic alpha-1 […]
18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease
Relkin, Norman R.,
Szabo, Paul,
Adamiak, Basia,
Burgut, Tuna,
Monthe, Carmen,
Lent, Richard W.,
Younkin, Steven,
Younkin, Linda,
Schiff, Richard,
Weksler, Marc E.
Intravenous immunoglobulin (IVIg) has been proposed as a potential agent for Alzheimer’s disease (AD) immunotherapy because it contains antibodies against beta-amyloid (Abeta). We carried out an open label dose-ranging study in 8 mild AD patients in which IVIg was added to approved AD therapies for 6 months, discontinued, and then resumed for another 9 months. […]